Loading
QUARTZ found that whole-brain radiotherapy added nothing measurable, in survival or quality of life, for lung cancer patients whose brain metastases could not be treated with surgery or radiosurgery.
QUARTZ randomised 538 patients with non-small-cell lung cancer and brain metastases unsuitable for resection or stereotactic radiosurgery to optimal supportive care with dexamethasone, with or without whole-brain radiotherapy (20 Gy in five fractions). Quality-adjusted life-years (46.4 vs 41.7 days) and overall survival (9.2 vs 8.5 weeks) did not differ meaningfully (Mulvenna and colleagues, Lancet 2016). The result restrained the routine use of whole-brain radiotherapy in patients with poor performance status.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
538 enrolled.
Shares Whole-brain radiotherapy (WBRT), Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag radiation-wave2.
Shares Whole-brain radiotherapy (WBRT), Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag radiation-wave2.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag radiation-wave2.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag radiation-wave2.
Shares Brain and spinal cord tumours (all types) and the tag radiation-wave2.
Shares Non-small-cell lung cancer and the tag radiation-wave2.
Shares Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain, Palliative radiotherapy, Lung cancer (all types), Non-small-cell lung cancer.
Shares Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain, Early integrated palliative care, Lung cancer (all types), Non-small-cell lung cancer.